Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL. Zhao J, et al. Among authors: ma z. J Immunother Cancer. 2023 Feb;11(2):e006055. doi: 10.1136/jitc-2022-006055. J Immunother Cancer. 2023. PMID: 36808075 Free PMC article. Clinical Trial.
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.
Wu YL, Wang CL, Sun Y, Liao ML, Guan ZZ, Yang ZM, Zhou QH, Lu S, Cheng Y, Liu XQ, Zhang XC, Zhou C, Wang J, Zhou Q, Song Y, Han BH, Ma ZY, Yang F, Wang Q, Chuai SK, Shao Y, He W, Zhu G, Xiong L, Wang JJ, Chen KN, Zhang L, Mao WM, Ma SL, Feng JF, Yang XN, Xu L, Chen G, Zhao J, Song QB, Shen-Tu Y, Qiao GB, Yu D, Yu SY, Hu Y, Chen M, Chen GY, Fan Y, Zhang HL, Liang J, Zhu GY, Cui JW, Yang JJ, Zhao Q, Zhao MF, Lu Y, Chang JH, Li JL, Yang Y, Hu J, Gu CD, Zhang YC, Zhong WZ. Wu YL, et al. ESMO Open. 2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017. ESMO Open. 2017. PMID: 28848676 Free PMC article. Review.
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.
Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, Feng JF, Ma SL, Wu G, Zhou CC, Chen KN, Cheng Y, He Y, Chen C, Wang Q, Lin JZ, Zhu B, Liu YP, Hu Y, Qiao GB, Zhou Q, Song QB, Wu N, Wu L, Huang C, Fu XL, Xiong JP, Hu J, Hu CP, Chang JH, Zhao Q, Zhao J, Zhou PH, Ma ZY, Chen Y, Zhang HL, Yang F, Wang JJ, Pan YY, Yang XN, Fan Y, Liu Z, Fan W, Yang N, Guan YF, Sun H, Zhong WZ. Wu YL, et al. Among authors: ma zy, ma sl. Transl Lung Cancer Res. 2018 Jun;7(3):428-436. doi: 10.21037/tlcr.2018.04.15. Transl Lung Cancer Res. 2018. PMID: 30050780 Free PMC article. Review.
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J. Wu YL, et al. Among authors: ma z. J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17. J Thorac Oncol. 2019. PMID: 30659987 Free article. Clinical Trial.
Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).
Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Song Y, et al. Am J Clin Oncol. 2019 May;42(5):432-439. doi: 10.1097/COC.0000000000000538. Am J Clin Oncol. 2019. PMID: 30950859 Free PMC article. Clinical Trial.
14,517 results
You have reached the last available page of results. Please see the User Guide for more information.